AzTrials
AzTrials

Diabetes Mellitus, Type 2NCT03807440

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

An observational study of Diabetes Mellitus, Type 2, run by Boehringer Ingelheim at 177 sites in 5 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a non-interventional study using existing data including medical chart review. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetes Mellitus, Type 2
What is being tested?
Empagliflozin, Sodium Glucose Transporter 2 inhibitor and Dipeptidyl-peptidase 4 inhibitor
How many people
4,083 participants
Where
177 sitesin 5 countries
Study dates
26 Aug 2019to 31 Aug 2021
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients (18 years of age or older) with Type 2 Diabetes diagnosis, naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), DPP4i (Dipeptidyl-peptidase 4 inhibitor) or GLP1a (Glucagon-like peptide 1 agonist) at index date were chosen.

Who may be able to join

  • Written informed consent prior to participation
  • Female and male patients age ≥ 18 years
  • Patients with T2D diagnosis
  • Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
  • Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

Who cannot join

  • Patients age < 18 years
  • Patients with diagnosis of other types of diabetes than T2D
  • Patients who do not provide written consent to the terms of the study

Trial locations and contacts

177 sites in 5 countries.

177 sites in 5 countries

Russia66 sites

  • Anturium, Center Nr.: 70036

    Barnaul, 656043

  • Central city hospital, Center Nr.: 70073

    Bataysk, 346880

  • Chelyabinsk regional clinical hospital, Center Nr.: 70069

    Chelyabinsk, 454076

  • Russian Medical Academy of Continuing Professional Education, Center Nr.: 70058

    Irkutsk, 664049

  • The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Center Nr.: 70037

    Izhevsk, 426039

  • Central City Hospital No. 18, Center Nr.: 70051

    Kazan', 420073

  • Kemerovo regional clinical hospital named S.V. Belyaev, Center Nr.: 70008

    Kemerovo, 50066

  • City Polyclinic No. 16, Center Nr.: 70067

    Khabarovsk, 680045

  • Kirov Clinical Hospital No. 7 named after V.I. Yurlova, Center Nr.: 70089

    Kirov, 610020

  • Krai clinical hospital Nr. 1 named after prof. S.V. Ochapovskogo, Center Nr.: 70049

    Krasnodar, 350086

  • Lipetsk Regional Hospital, Center Nr.: 70046

    Lipetsk, 398902

  • SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080

    Moscow, 109240

  • Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042

    Moscow, 115409

  • National Medical Research Center for Endocrinology, Center Nr.: 70025

    Moscow, 117036

  • City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70043

    Moscow, 117218

  • City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70045

    Moscow, 117218

  • Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032

    Moscow, 119034

  • Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70041

    Moscow, 119034

  • Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70081

    Moscow, 119034

  • Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70084

    Moscow, 119034

  • Vessel Clinic, Center Nr.: 70011

    Moscow, 125252

  • City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082

    Moscow, 127273

  • City Clinical Hospital named after V.V. Veresaeva of the Moscow Department of Health, Center Nr.: 70003

    Moscow, 127644

  • City Polyclinic No. 1, Center Nr.: 70074

    Nal'chik, 360051

  • City clinical hospital #12 of Sormovskiy district of Nizhniy Novgorod, Center Nr.: 70018

    Nizhny Novgorod, 603003

  • Privolzhsky Research Medical University, Center Nr.: 70085

    Nizhny Novgorod, 603005

  • Novokuznetsk City Clinical Hospital No. 1, Center Nr.: 70050

    Novokuznetsk, 654027

  • AVICENNA, Center Nr.: 70065

    Novosibirsk, 630007

  • City Clinical Polyclinic #16, Center Nr.: 70056

    Novosibirsk, 630078

  • Novosibirsk State Medical University, Center Nr.: 70059

    Novosibirsk, 6300911

  • AVICENNA, Center Nr.: 70064

    Novosibirsk, 630099

  • Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095

    Penza, 440026

  • Private Clinic Salon Roden, Center Nr.: 70086

    Perm, 614000

  • City clinical hospital 5, Center Nr.: 70057

    Perm, 614010

  • City clinical hospital 5, Center Nr.: 70070

    Perm, 614010

  • City polyclinic #16 of the City Rostov-on-Don, Center Nr.: 70027

    Rostov-on-Don, 344092

  • North-West State Medical University named after II. Mechnikov, Center Nr.: 70053

    Saint Petersbug, 191015

  • North-West State Medical University named after II. Mechnikov, Center Nr.: 70077

    Saint Petersbug, 191015

  • First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70024

    Saint Petersburg, 197022

  • First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70087

    Saint Petersburg, 197022

  • Medilux-TM, Center Nr.: 70005

    Saint Petersburg, 197227

  • V.A. Almazov National Medical Research Center, Center Nr.: 70071

    Saint Petersburg, 197341

  • AntMed, Center Nr.: 70034

    Saint Petersburg, 197349

  • Dr. Tsiberkin, Center Nr.: 70048

    Saint Petersburg, 197349

  • City Pokrovskaya Hospital, Center Nr.: 70022

    Saint Petersburg, 199106

  • Zabotlivyi Doktor, Center Nr.: 70016

    Saint Petersburg, 966550

  • Samara city polyclinic Nr. 9 of Oktyabrskiy district, Center Nr.: 70028

    Samara, 443110

  • Samara city consulting and diagnostic polyclinic nr. 14, Center Nr.: 70029

    Samara, 443111

  • Clinical Hospital of the Saratov city, Center Nr.: 70090

    Saratov, 410004

  • LLC clinic "Family Doctor", Center Nr.: 70093

    Saratov, 410012

  • Multifunctional Medical Clinic "Sova", Center Nr.: 70030

    Saratov, 410056

  • Regional Endocrinological Dispensary, Center Nr.: 70078

    Stavropol, 355045

  • Tyumen State Medical University, Center Nr.: 70066

    Tyumen, 625023

  • City clinical hospital, Center Nr.: 70019

    Ufa, 450014

  • City Polyclinic No.2, Center Nr.: 70062

    Ulan-Ude, 670031

  • Limited Liability Company "CENTER", Center Nr.: 70060

    Vladivostok, 690017

  • Regional Clinical Hospital No. 2, Center Nr.: 70092

    Vladivostok, 690035

  • Regional Clinical Hospital No. 2, Center Nr.: 70068

    Vladivostok, 690105

  • Volgograd Regional Clinical Hospital No. 3, Center Nr.: 70076

    Volgograd, 400001

  • Clinical Polyclinic No.28, Center Nr.: 70040

    Volgograd, 400117

  • Voronezh City Clinical Hospital #11, Center Nr.: 70035

    Voronezh, 394042

  • State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70017

    Voronezh, 394077

  • State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70033

    Voronezh, 394077

  • State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70055

    Voronezh, 394077

  • Limited Liability Company "Uralsky Medical Center", Center Nr.: 70063

    Yekaterinburg, 620102

  • Scientific and Practical Center of Specialized Types of Medical Care "Uralskij Institute of Cardiology", Center Nr.: 70079

    Yekaterinburg, 620144

Other trials in Russia

Czechia58 sites

  • Michal Brada, Center Nr.: 42001

    Beclav, 69002

  • Dr. Kovaová, Center Nr.: 42069

    Beroun, 26656

  • Practice Dr. Alice Sýkorová, Center Nr.: 42057

    Bílina, 418 01

  • MUDr. Alica Vesela, Center Nr.: 42030

    Broumov, 55001

  • EUC Klinika eské Budjovice, Center Nr.: 42052

    Eské Budjovice, 37001

  • Lékaský dm Géko, Center Nr.: 42059

    Eské Budjovice, 37011

  • Barbara Buzová, Center Nr.: 42003

    Havíov, 73601

  • Zaviatiová, Petra, Center Nr.: 42004

    Havíov, 73601

  • Radana Syslová, Center Nr.: 42035

    Hlušovice, 78314

  • Pavel Kasík, Center Nr.: 42046

    Hoovice, 268 31

  • Practice Dr. Petr Maule, Center Nr.: 42054

    Humpolec, 39601

  • Mediab Jihlava s.r.o., Center Nr.: 42066

    Jihlava, 58601

  • Practice MUDr. Gita Markofová, Center Nr.: 42053

    Karlovy Vary, 36066

  • Dr. Konená, Center Nr.: 42036

    Karviná - Staré Msto, 73301

  • Practice Zdzislaw Wranka, Center Nr.: 42072

    Karviná-Hranice, 73301

  • Pavel Tománek, Center Nr.: 42028

    Kopivnice, 74221

  • DIABET HELP s.r.o., Center Nr.: 42058

    Kralupy nad Vltavou, 27801

  • MUDr.Tomáš Edelsberger, Center Nr.: 42007

    Krnov, 79401

  • Jitka Hasalová, Center Nr.: 42010

    Kromiz, 76901

  • árka Drinková, Center Nr.: 42038

    Lede Nad Sázavou, 58401

  • Martina Košková, Center Nr.: 42047

    Mladá Boleslav, 29350

  • Dobromila Vykoupilová, Center Nr.: 42033

    Nmice Nad Hanou, 79827

  • Karel Churavý, Center Nr.: 42005

    Nový Jiín, 74101

  • árka Kubánková, Center Nr.: 42048

    Nymburk, 28802

  • Agentura Science Pro spol. s.r.o., Center Nr.: 42002

    Olomouc, 772 00

  • Anna Rancová, Center Nr.: 42025

    Olomouc, 77900

  • Josef íný, Center Nr.: 42026

    Opava, 74601

  • MUDr.Tomáš Hrdina, Center Nr.: 42015

    Opono, 51773

  • Dr. Šeptáková, Center Nr.: 42074

    Ostrava, 700 30

  • Practice Dr. René Turínek, Center Nr.: 42034

    Ostrava, 70200

  • MUDr. Eva Raická, Center Nr.: 42024

    Ostrava, 71000

  • Jitka Homolová, Center Nr.: 42012

    Ostrava, 72880

  • Radka Nágelová, Center Nr.: 42020

    Ostrava Poruba, 70800

  • AIDIN VK s.r.o., Center Nr.: 42017

    Perov, 75301

  • MUDr. Vra Prýmková, Center Nr.: 42070

    Píbram, 26101

  • Zdenk Jankovec, Center Nr.: 42044

    Plze, 30100

  • Diabetologická a interní ambulance, Center Nr.: 42064

    Podbrady, 29001

  • MUDr. Jana Houdová, Center Nr.: 42068

    Prague, 10000

  • Practice Dr. Milena Peterková, Center Nr.: 42063

    Prague, 12143

  • MUDr.Michala Pelikánová s.r.o., Center Nr.: 42055

    Prague, 14000

  • Markéta Hovorková, Center Nr.: 42042

    Prague, 14021

  • Jakub Hron, Center Nr.: 42043

    Prague, 14300

  • Milan Fleka, Center Nr.: 42041

    Prague, 15000

  • Jií Jón, Center Nr.: 42045

    Prague, 15030

  • Practice Dr. Lucie Kufová, Center Nr.: 42062

    Prague, 15030

  • Practice Dr. Ida Reissová, Center Nr.: 42056

    Prague, 16300

  • Barbora Diepoltová, Center Nr.: 42037

    Prague, 19014

  • Practice Dr. Petronela Janeková, Center Nr.: 42065

    Rumburk, 40801

  • Practice Dr. Miroslav Lindovský, Center Nr.: 42051

    Sokolov, 35601

  • Dana Fialkoviová, Center Nr.: 42040

    Strakonice, 38601

  • Marek Frydrych, Center Nr.: 42008

    Tebí, 674 01

  • Marek Frydrych, Center Nr.: 42077

    Tebí, 674 01

  • Diabetologická ambulance s.r.o., Center Nr.: 42076

    Uherské Hradišt, 68601

  • Dr. Hrmová, Center Nr.: 42073

    Vlašim, 25801

  • Lubomír Kudlej, Center Nr.: 42050

    Vrchlabí, 54301

  • AdiaMed s.r.o., Center Nr.: 42009

    Vsetín, 75501

  • EUC Klinika Zlín a.s., Center Nr.: 42075

    Zlín, 76001

  • Robin Urbánek, Center Nr.: 42029

    Zlín, 76001

Other trials in Czechia

Poland28 sites

  • Gabinet Diabetologiczno- Internistyczny Katarzyna Wasilewska, Center Nr.: 48011

    Biaystok, 15-591

  • NZOZ DIAMED Sp. z o.o., Center Nr.: 48061

    Czechowice-Dziedzice, 43-502

  • Prywatny Gabinet Lekarski dr n. med. Joanna Sawer-Szewczyk, Center Nr.: 48055

    Czyca, 99-100

  • Zespó Opieki Zdrowotnej w czycy, Center Nr.: 48054

    Czyca, 99-100

  • NZOZ Sal Med, Center Nr.: 48047

    Dzieroniów, 58-200

  • Poradnia Diabetologiczna, Center Nr.: 48028

    Gorlice, 38-300

  • Indywidualna Specjalistyczna Praktyka Lekarska Piotr Piskozub Specjalista Diabetolog, Center Nr.: 48042

    Jelenia Góra, 58-506

  • NZOZ Poradnia Diabetologiczna, Center Nr.: 48038

    Konin, 62-504

  • Zakad Opieki Medycznej Sanatio; Sp. Z. o.o., Center Nr.: 48030

    Krakow, 31-548

  • Prywatny Gabinet Lekarski Tomasz Wierzykowski, Center Nr.: 48053

    Kutno, 99-300

  • Indywidualna Specjalistyczna Praktyka Lekarska Magorzata Poskoska-Lemaska, Center Nr.: 48035

    Kwidzyn, 82-500

  • Indywidualna Specjalistyczna Praktyka Lekarska Barbara Soróbka, Center Nr.: 48001

    Legnica, 59-220

  • Poradnia Cukrzycowa SP ZOZ w Lesku, Center Nr.: 48024

    Lesko, 38-600

  • Lumed Sp. z o.o., Center Nr.: 48032

    Lubaczów, 37-600

  • DIABETA-CARE Sp.z o.o., Center Nr.: 48008

    Lubin, 59-300

  • Poradnia Diabetologiczna Dr. mudziska, Center Nr.: 48013

    Nako Nad Noteci, 89-100

  • Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Center Nr.: 48007

    Nowy Scz, 33-300

  • Poradnia Diabetologiczna Dr. Adamczyk-Gajda, Center Nr.: 48031

    Olenica, 56-400

  • MED-ART Sp. z o.o., Center Nr.: 48052

    Orzesze, 43-180

  • Indywidualna Specjalistyczna Praktyka Lekarska Wiesawa Fischer, Center Nr.: 48020

    Ostrów Wielkopolski, 63-400

  • Prywatny Gabinet Lekarski azuka, Center Nr.: 48026

    Parczew, 21-200

  • Powiatowy Szpital Specjalistyczny w Stalowej Woli, Center Nr.: 48056

    Stalowa Wola, 37-450

  • Prywatny Gabinet Lekarski dr n. med. Piotr Gryglas, Center Nr.: 48059

    Warsaw, 03-922

  • Poradnia Diabetologiczna Szpitala Powiatowego w Wicborku, Center Nr.: 48003

    Wicbork, 89-410

  • Orodek Praktyka Lekarska Konrad Strzelczyk, Center Nr.: 48012

    Woomin, 05-200

  • Poradnia Diabetologiczna SPZZOZ w Wyszkowie, Center Nr.: 48067

    Wyszków, 07-200

  • Wojewódzka Poradnia dla Chorych na Cukrzyc, Center Nr.: 48025

    Zabrze, 41-800

  • Cardiomed, Center Nr.: 48019

    Zielona Góra, 65-001

Other trials in Poland

Bulgaria15 sites

  • MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903

    Byala, 7100

  • MC "Diamedical 2013" OOD, Center Nr.: 35902

    Dimitrovgrad, 6400

  • MBAL- Dobrich AD, Center Nr.: 35916

    Dobrich, 9300

  • Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904

    Dupnitsa, 2600

  • MHAT "Medline Clinic", Center Nr.: 35911

    Plovdiv, 4000

  • MC Kuchuk Parij OOD, Center Nr.: 35906

    Plovdiv, 4030

  • MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909

    Rakovski, 4150

  • "Medical Center-Razgrad"OOD, Center Nr.: 35910

    Razgrad, 7200

  • DCC 1 - Russe EOOD, Center Nr.: 35905

    Rousse, 7000

  • MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915

    Sliven, 8800

  • MC Polimed AD, Center Nr.: 35907

    Sofia, 1303

  • MC Gina - LZ SIMP EOOD, Center Nr.: 35918

    Sofia, 1463

  • MC "Vitaclinic" EOOD, Center Nr.: 35901

    Sofia, 1680

  • MC Kalimat EOOD, Center Nr.: 35914

    Sofia, 1680

  • Acibadem City Clinic Medical Center Varna EOOD, Center Nr.: 35908

    Varna, 9002

Other trials in Bulgaria

Hungary10 sites

  • Bajcsy-Zsilinszky Kórház és Rendelintézet, Center Nr.: 36019

    Budapest, 1106

  • Jahn Ferenc Dél-pesti Kórház és Rendelintézet, Center Nr.: 36014

    Budapest, 1204

  • Debreceni Egyetem Klinikai Központ, Kardiológiai Klinika, Center Nr.: 36006

    Debrecen, 4032

  • Kátai Gábor Kórház, Diabetológia Szakrendelés, Center Nr.: 36007

    Karcag, 5300

  • Practice Dr. Lelkesi Anita, Center Nr.: 36013

    Mátészalka, 4700

  • Nagyatádi Kórház, Center Nr.: 36021

    Nagyatád, 7500

  • Nyírségi Diabetes Centrum, Center Nr.: 36024

    Nyíregyháza, 4400

  • Dr. Wagner Zoltán, Center Nr.: 36020

    Pécs, 7625

  • Siófoki Kórház Rendelintézet, Center Nr.: 36004

    Siófok, 8600

  • Soproni Gyógyközpont, Center Nr.: 36018

    Sopron, 9400

Other trials in Hungary

About this study

Official title: CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries

This is a non-interventional study using existing data including medical chart review.

Being tested
Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor, Glucagon-like peptide 1 agonist
Medical subject headings
Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EmpagliflozinDrug

    Also called Jardiance® Synjardy® Trajenta® Jentadueto®

    Empagliflozin

  • Sodium Glucose Transporter 2 inhibitorDrug

    Also called Jardiance® Synjardy® Trajenta® Jentadueto®

    Sodium Glucose Transporter 2 inhibitor

  • Dipeptidyl-peptidase 4 inhibitorDrug

    Also called Jardiance® Synjardy® Trajenta® Jentadueto®

    Dipeptidyl-peptidase 4 inhibitor

  • Glucagon-like peptide 1 agonistDrug

    Also called Jardiance® Synjardy® Trajenta® Jentadueto®

    Glucagon-like peptide 1 agonist

Study groups in NCT03807440
Study groupRoleWhat they receive
Subjects with Diabetes Mellitus, Type 2Not described
Receives: Drug: Empagliflozin; Drug: Sodium Glucose Transporter 2 inhibitor; Drug: Dipeptidyl-peptidase 4 inhibitor; Drug: Glucagon-like peptide 1 agonist

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist

    Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  2. Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist

    Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported.

    The concomitant T2D medications reported are:

    • Metformin
    • Sulfonylurea
    • Acarbose
    • Pioglitazone
    • Insulin
    • Others

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  3. Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist

    Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported.

    The reported concomitant CVD and/or chronic CKD medications are:

    • Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs)
    • Statins
    • Low dose aspirin
    • Beta blockers
    • Diuretics
    • Others

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  4. Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  5. Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The reported categories of gender are:

    • Female
    • Male

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  6. Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  7. Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The reported categories of race are:

    • Black
    • Non-black

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  8. Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  9. Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The reported categories of gender are:

    • Female
    • Male

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  10. Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  11. Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The reported categories of race are:

    • Black
    • Non-black

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  12. Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  13. Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The reported categories of gender are:

    • Female
    • Male

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  14. Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter^2 (kg/m^2)).

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  15. Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The reported categories of race are:

    • Black
    • Non-black

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  16. Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  17. Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

    Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  18. Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

    Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  19. Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  20. Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The reported categories of percentage (%) of glycosylated hemoglobin are:

    • <8.5%
    • ≥8.5%
    • Missing

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  21. Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  22. Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The reported categories of percentage of glycosylated hemoglobin are:

    • <8.5%
    • ≥8.5%
    • Missing

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  23. Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c [%]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  24. Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The reported categories of percentage of glycosylated hemoglobin are:

    • <8.5%
    • ≥8.5%
    • Missing

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  25. 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  26. 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  27. 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  28. Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  29. Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  30. Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

Secondary outcomes (40)

  1. Number of Patients With Any Type of Cardiovascular Disease (CVD)

    Number of patients with cardiovascular disease (CVD) is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  2. Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment

    Number of patients with chronic kidney disease (CKD) by physician's assessment (patients for whom CKD was reported as a comorbidity) is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  3. Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status

    Number of patients with documentation of estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) status is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  4. Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status

    Number of patients with Chronic Kidney Disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  5. Number of Patients in Each Category of the Different Types of Cardiovascular Disease

    Number of patients in each category of the different types of cardiovascular disease is reported.

    The following types of cardiovascular diseases are reported:

    • Myocardial infarction
    • Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG))
    • Ischemic heart disease
    • Congestive heart failure
    • Stroke
    • Peripheral arterial disease

    The categories reported for each type of cardiovascular disease are:

    • Yes
    • No
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  6. Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography

    Number of patients in each category of the different types of congestive heart failure (CHF) which was confirmed by echocardiography is reported.

    The reported categories of congestive heart failure confirmed by echocardiography are:

    • Yes
    • No
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  7. Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist

    Number of patients with any type of cardiovascular disease (CVD) or without CVD according to prescribing specialist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  8. Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist

    Number of patients with chronic kidney (CKD) and without CKD by physician's assessment according to prescribing specialist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  9. Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist

    Number of patients with chronic kidney disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status - according to prescribing specialist is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  10. Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  11. Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of different types of cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    The following types of cardiovascular diseases are reported:

    • Myocardial infarction
    • Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG))
    • Ischemic heart disease
    • Congestive heart failure
    • Stroke
    • Peripheral arterial disease

    The categories reported for each type of cardiovascular disease are:

    • Yes
    • No
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  12. Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of congestive heart failure (CHF) confirmed by echocardiography according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  13. Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist

    Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  14. Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  15. Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  16. Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) or without CKD by physician's assessment according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  17. Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) and without CKD by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  18. Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of employment status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    The categories of employment status are:

    • Employed
    • Not employed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  19. Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of family status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    The categories of family status are:

    • Single
    • Married
    • Divorced
    • Widowed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  20. Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    The categories of insurance status are:

    • Not insured
    • Statutory insured
    • Privately insured
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  21. Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The categories of employment status are:

    • Employed
    • Not employed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  22. Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The categories of family status are:

    • Single
    • Married
    • Divorced
    • Widowed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  23. Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The categories of insurance status are:

    • Not insured
    • Statutory insured
    • Privately insured
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  24. Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The categories of employment status are:

    • Employed
    • Not employed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  25. Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The categories of family status are:

    • Single
    • Married
    • Divorced
    • Widowed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  26. Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The categories of insurance status are:

    • Not insured
    • Statutory insured
    • Privately insured
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  27. Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The categories of employment status are:

    • Employed
    • Not employed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  28. Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The categories of family status are:

    • Single
    • Married
    • Divorced
    • Widowed
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  29. Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The categories of insurance status are:

    • Not insured
    • Statutory insured
    • Privately insured
    • Unknown

    Measured: At study index date 1 (i.e. between September 2018 and December 2018).

  30. Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    The categories of status of T2D medication are:

    • Discontinued
    • Continued

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  31. Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The categories of status of T2D medication are:

    • Discontinued
    • Continued

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  32. Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The categories of status of T2D medication are:

    • Discontinued
    • Continued

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  33. Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The categories of status of T2D medication are:

    • Discontinued
    • Continued

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  34. Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country

    Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication by country is reported.

    The categories of reason for discontinuation of T2D medication are:

    • Lack of efficacy
    • Medication administration
    • Financial burden regarding co-payment
    • Lost to follow-up
    • Adverse event
    • Other

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  35. Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1

    Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

    The categories of reason for discontinuation of T2D medication are:

    • Lack of efficacy
    • Medication administration
    • Financial burden regarding co-payment
    • Lost to follow-up
    • Adverse event
    • Other

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  36. Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

    Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

    The categories of reason for discontinuation of T2D medication are:

    • Lack of efficacy
    • Medication administration
    • Financial burden regarding co-payment
    • Lost to follow-up
    • Adverse event
    • Other

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  37. Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

    Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

    The categories of reason for discontinuation of T2D medication are:

    • Lack of efficacy
    • Medication administration
    • Financial burden regarding co-payment
    • Lost to follow-up
    • Adverse event
    • Other

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  38. Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

    Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

    The categories of reason for discontinuation of T2D medication are:

    • Lack of efficacy
    • Medication administration
    • Financial burden regarding co-payment
    • Lost to follow-up
    • Adverse event
    • Other

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  39. Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist

    Number of patients for each type of physician specialties involved in decision for T2D therapy discontinuation according to prescribing specialist is reported.

    Measured: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

  40. Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication

    Time to discontinuation of type 2 diabetes (T2D) treatment according to study medication is reported.

    Time to discontinuation of T2D medication was estimated by Kaplan-Meier analysis. Patients who did not discontinue study medication at study index date 2 were censored.

    Measured: From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2019
  2. Study start26 Aug 2019
  3. Primary completion31 Aug 2021
  4. Study completion31 Aug 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
4,083 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03807440
Sponsor's protocol ID
1245-0187
Status last verified
Feb 2023
First submitted
15 Jan 2019
Last updated
1 Dec 2023
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

Publications

  • Prazny M, Suplotova L, Gumprecht J, Kamenov Z, Fulop T, Medvedchikov A, Rosenzweig D, Aleksandric M. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY(R) study. Cardiovasc Diabetol. 2022 Oct 8;21(1):203. doi: 10.1186/s12933-022-01631-4.

    PubMed 36209118

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Mellitus, Type 2, run by Boehringer Ingelheim at 177 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 177 sites in Russia, Czechia, Poland, Bulgaria, Hungary. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Dec 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist (time frame: At study index date 1 (i.e. between September 2018 and December 2018).). The study lists 30 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03807440, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in